FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Aug 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5091128012 | Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5091129016 | Leuprolide acetate 22.5 mg powder for prolonged-release suspension for injection vial | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5091130014 | Leuprorelin acetate 22.5 mg powder for prolonged-release suspension for injection vial | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Is a | Leuprorelin only product in parenteral dose form | true | Inferred relationship | Some | ||
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Has manufactured dose form | Powder for prolonged-release suspension for injection (dose form) | true | Inferred relationship | Some | ||
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Has unit of presentation | Vial (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Plays role | Antineoplastic therapeutic role | false | Inferred relationship | Some | ||
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Leuprorelin acetate | true | Inferred relationship | Some | 1 | |
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Leuprorelin acetate | true | Inferred relationship | Some | 1 | |
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Vial (unit of presentation) | true | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets